Chronic Spontaneous Urticaria Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Chronic Spontaneous Urticaria Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Spontaneous Urticaria pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Chronic Spontaneous Urticaria Pipeline. Dive into DelveInsight's comprehensive report today! @ Chronic Spontaneous Urticaria Pipeline Outlook- https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Spontaneous Urticaria Pipeline Report
• In May 2025, Celldex Therapeutics announced a study is to establish the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) inadequately controlled by non-sedating second generation H1-antihistamines in comparison to placebo.
• In May 2025, Novartis Pharmaceuticals conducted a study is to collect long-term efficacy, safety and tolerability data on remibrutinib in a selected group of participants with Chronic Spontaneous Urticaria (CSU) who previously completed the treatment phase of remibrutinib preceding Phase 3 studies. This study will also fulfill the Novartis commitment to provide post-trial access to participants who have completed the preceding Phase 3 studies, where applicable.
• In May 2025, InflaRx GmbH organized a study duration for an individual subject includes screening (14 days), the treatment period (28 days) and the observational follow-up period of 28 days, in total 70 days ± 6 days. All subjects will receive IMP for 28 days followed by one End of Study (EOS) visit, 4 weeks after EOT visit.
• DelveInsight's Chronic Spontaneous Urticaria Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Chronic Spontaneous Urticaria treatment.
• The leading Chronic Spontaneous Urticaria Companies such as United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier and others.
• Promising Chronic Spontaneous Urticaria Pipeline Therapies such as EVO756, Barzolvolimab, CMAB007, Xolair, JYB1904, Omalizumab, Briquilimab, CT-P39, TAS5315, LOU064 and others.

Stay ahead with the most recent pipeline outlook for Chronic Spontaneous Urticaria. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Chronic Spontaneous Urticaria Treatment Drugs- https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Spontaneous Urticaria Emerging Drugs Profile

• Dupilumab: Sanofi
Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across 60 clinical trials involving more than 10,000 patients with various chronic diseases driven in part by type 2 inflammation.
Dupixent is approved for use in certain patients with atopic dermatitis, asthma, CRSwNP or EoE in different age populations. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including chronic spontaneous urticaria, which is in the preregistration developmental stage.

• Tezepelumab: Amgen
Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin (TSLP). The drug is in Preregistration for Asthma treatment; in Phase III for rhinosinusitis; in Phase II clinical studies for the treatment of chronic urticarial and chronic obstructive pulmonary disease. Tezepelumab is being developed in collaboration with AstraZeneca.

• Barzolvolimab: Celldex Therapeutics
Barzolvolimab (CDX-0159) is a humanized monoclonal antibody that specifically binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival, and activity of mast cells. In certain inflammatory diseases, mast cell activation plays a central role in the onset and progression of the disease. Currently, the drug is being evaluated in the Phase II development stage for the treatment of chronic spontaneous urticaria.

The Chronic Spontaneous Urticaria Pipeline Report Provides Insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Spontaneous Urticaria with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Spontaneous Urticaria Treatment.
• Chronic Spontaneous Urticaria Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Chronic Spontaneous Urticaria Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Spontaneous Urticaria market

Explore groundbreaking therapies and clinical trials in the Chronic Spontaneous Urticaria Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New Chronic Spontaneous Urticaria Drugs- https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Spontaneous Urticaria Companies
United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier and others.

Chronic Spontaneous Urticaria pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intravenous
• Subcutaneous
• Oral
• Intramuscular

Chronic Spontaneous Urticaria Products have been categorized under various Molecule types such as
• Monoclonal antibody
• Small molecule
• Peptide

Unveil the future of Chronic Spontaneous Urticaria Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Chronic Spontaneous Urticaria Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Spontaneous Urticaria Pipeline Report
• Coverage- Global
• Chronic Spontaneous Urticaria Companies- United BioPharma, Teva Pharmaceuticals Development, Inc., Amgen, Novartis Pharmaceuticals, Allakos Inc., Sanofi, Celltrion, Celldex Therapeutics, MICROBIO GROUP, Escient Pharmaceuticals, Jasper Therapeutics, Glenmark Pharmaceuticals, Taiho Pharmaceuticals, ValenzaBio, Carna Biosciences, Servier and others.
• Chronic Spontaneous Urticaria Pipeline Therapies- EVO756, Barzolvolimab, CMAB007, Xolair, JYB1904, Omalizumab, Briquilimab, CT-P39, TAS5315, LOU064 and others.
• Chronic Spontaneous Urticaria Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Chronic Spontaneous Urticaria Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Chronic Spontaneous Urticaria Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Chronic Spontaneous Urticaria Companies, Key Products and Unmet Needs- https://www.delveinsight.com/sample-request/chronic-spontaneous-urticaria-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Contents
1. Introduction
2. Executive Summary
3. Chronic Spontaneous Urticaria: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Chronic Spontaneous Urticaria- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Dupilumab: Sanofi
9. Drug profiles in the detailed report.....
10. Late Stage Products (Phase III)
11. Remibrutinib: Novartis
12. Drug profiles in the detailed report.....
13. Mid Stage Products (Phase II)
14. Tezepelumab: Amgen
15. Drug profiles in the detailed report.....
16. Early Stage Products (Phase I)
17. Drug: Company
18. Drug profiles in the detailed report.....
19. Preclinical and Discovery Stage Products
20. Briquilimab: Jasper Therapeutics
21. Drug profiles in the detailed report.....
22. Inactive Products
23. Chronic Spontaneous Urticaria Key Companies
24. Chronic Spontaneous Urticaria Key Products
25. Chronic Spontaneous Urticaria- Unmet Needs
26. Chronic Spontaneous Urticaria- Market Drivers and Barriers
27. Chronic Spontaneous Urticaria- Future Perspectives and Conclusion
28. Chronic Spontaneous Urticaria Analyst Views
29. Chronic Spontaneous Urticaria Key Companies
30. Appendix

List of Top Selling Market Research Reports in 2025

Radiation retinopathy market- https://www.delveinsight.com/sample-request/radiation-retinopathy-market
Immune checkpoints activators market- https://www.delveinsight.com/report-store/immune-checkpoint-inhibitors-market
Cystic fibrosis Market- https://www.delveinsight.com/report-store/cystic-fibrosis-market
Palmoplantar pustulosis market- https://www.delveinsight.com/report-store/palmoplantar-pustulosis-market
Smoking cessation market- https://www.delveinsight.com/report-store/smoking-cessation-and-nicotine-addiction-market
Surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
Tay-Sachs market- https://www.delveinsight.com/report-store/tay-sachs-disease-market
Attention deficit hyperactivity disorder market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Medical marijuana market- https://www.delveinsight.com/report-store/medical-marijuana-market
Open angle glaucoma market- https://www.delveinsight.com/report-store/glaucoma-market
Acute myeloid leukemia market- https://www.delveinsight.com/report-store/acute-myeloid-leukemia-aml-market
Asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
Bone growth stimulators market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
Cardiogenic shock market- https://www.delveinsight.com/report-store/cardiogenic-shock-market
Pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
Pediatric brain tumor market- https://www.delveinsight.com/report-store/pediatric-brain-tumors-market
Pelizaeus-merzbacher disease market- https://www.delveinsight.com/report-store/pelizaeus-merzbacher-disease-market
Peritoneal carcinomatosis market- https://www.delveinsight.com/report-store/peritoneal-carcinomatosis-pc-market
Pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.